Group 1: Merck & Co. - Merck's Q4 worldwide sales increased by 5% to $16.4 billion, with a full-year revenue exceeding $65 billion, driven primarily by oncology sales [2] - Keytruda, a major oncology drug, saw sales rise by 7% to nearly $32 billion, constituting almost half of Merck's total annual revenue [2] - New therapies are contributing to sales growth, with Winrevair generating $1.4 billion and Capvaxix bringing in just under $800 million in their first year [3] - Merck's guidance for 2026 revenue is around $66 billion, indicating a flat outlook compared to the current year [3] Group 2: Pfizer - Pfizer's full-year 2025 revenue decreased by 2% to approximately $63 billion, but oncology drugs like Padcev and Lorbrena showed growth [4] - Adjusted EPS for Pfizer rose by 4% to $3.22, supported by expanded margins and stable costs [4] - For 2026, Pfizer forecasts revenue between $59.5 billion and $62.5 billion, with adjusted EPS expected to be between $2.80 and $3.00 [5] - Pfizer's management is optimistic about a busy pipeline with around 20 pivotal study starts planned for the year, aiming to restore growth despite ongoing challenges from patent expirations and pricing pressures [5]